Literature DB >> 10671685

Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma.

C C Hsia1, Y Nakashima, S S Thorgeirsson, C C Harris, M Minemura, S Momosaki, N J Wang, E Tabor.   

Abstract

Mutations of the p53 tumor suppressor gene are common in hepatocellular carcinomas (HCCs). Detection of mutations by sequencing provides more information than immunohistochemical staining, but the equipment needed and the time required make it less practical for use in large-scale studies or in studies in developing countries. The degree of correlation between results obtained with these two methods has been studied in various tumors but has not been well-established in human HCCs. Paraffin sections of HCCs of 28 patients from Qidong, China were immunohistochemically stained using monoclonal antibody to p53. In addition, exons 5-8 of the p53 gene were sequenced in these HCCs. Of the 28 HCCs, nine had 0-9% of nuclei stained for p53, and 19 had 50-95% stained. Mutations in p53 exons 5-8 were found in 17/28 (61%) HCCs, including 15 at codon 249 (exon 7), one at codon 198 (exon 6), and one at codon 175 (exon 5). Among these 17 cases with p53 mutations, 16 cases (94%) had 50-95% of nuclei stained. Among 11 HCCs with no mutations by sequencing, 8 were also negative by immunohistochemistry (0-9% of nuclei stained) (73%) (the five HCCs with no staining whatsoever all had wild-type p53). Immunohistochemical staining to detect p53 mutations in human HCCs detected most mutations that were detected by sequencing (94% sensitivity, 73% specificity), and this method is therefore suitable when sequencing cannot be performed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10671685

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation.

Authors:  Michael A Nalesnik; George Tseng; Ying Ding; Guo-Sheng Xiang; Zhong-liang Zheng; YanPing Yu; James W Marsh; George K Michalopoulos; Jian-Hua Luo
Journal:  Am J Pathol       Date:  2012-02-08       Impact factor: 4.307

2.  Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization.

Authors:  Yong-Song Guan; Yuan Liu; Long Sun; Xiao Li; Qing He
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

3.  p19Arf inhibits aggressive progression of H-ras-driven hepatocellular carcinoma.

Authors:  Dragana Kopanja; Shuo Huang; Mohamed Rizwan Haroon Al Raheed; Grace Guzman; Pradip Raychaudhuri
Journal:  Carcinogenesis       Date:  2018-03-08       Impact factor: 4.944

4.  p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up.

Authors:  Yong-Song Guan; Yuan Liu; Qing He; Xiao Li; Lin Yang; Ying Hu; Zi La
Journal:  World J Gastroenterol       Date:  2011-04-28       Impact factor: 5.742

5.  p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma.

Authors:  Y S Guan; Y Liu; X P Zhou; X Li; Q He; L Sun
Journal:  Gut       Date:  2005-05-05       Impact factor: 23.059

6.  Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis.

Authors:  Chaobin He; Yu Zhang; Xiaojun Lin
Journal:  J Gastrointest Surg       Date:  2018-02-12       Impact factor: 3.452

7.  Immunohistochemical Determination of p53 Protein Overexpression for Predicting p53 Gene Mutations in Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Jiangbo Liu; Wei Li; Miao Deng; Dechun Liu; Qingyong Ma; Xiaoshan Feng
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

8.  Combined effect of recombinant human adenovirus p53 and curcumin in the treatment of liver cancer.

Authors:  Juan Qu; Wei Lu; Ming Chen; Wei Gao; Cong Zhang; Bin Guo; Jizhi Yang
Journal:  Exp Ther Med       Date:  2020-08-26       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.